Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) Antisense therapeutics are species specific because they are based on the genomic code. Although sequences may be relatively conserved among species, typical target regions for antisense therapeutics will differ by at least several bases between species. Therefore, to define pharmacologic effects, species-specific homologues of the human target must be identified and tested in the appropriate animal model. One exception is the use of human
ANTISENSE THERAPEUTICS
Antisense therapeutics are synthetic oligonucleotides targeting molecular mechanisms of disease at the mRNA level, which results in the decrease in aberrant protein production (7) . These therapeutics offer the potential of extraordinary specificity, which is derived from the genetic code and Watson-Crick base pairing. In Phosphodiester ODNs are rapidly degraded by nucleases. Modification of the natural phosphodiester ODN is essential for survivability of these agents when administered into humans or animals. The P=S backbone modification provides stability against nuclease degradation and allows the administration of these compounds for local and systemic therapies. Additional modifications of oligonucleotides have focused on increasing further the stability of these macromolecules and increasing target hybridization affinity. The primary modifcations currently being explored involve the 2' position on the ribose and the linkages of the nucleotide backbone (2, 9) . The 2' position modifications involve alkylation and halogenation ; the primary intent of these modifications is to protect a phosphodiester backbone from nuclease degradation. In addition, numerous backbone modifications have been evaluated to protect oligonucleotides from nuclease degradation (15) . Modifications (19) . Rather, toxicities induced by P=S ODNs appear similar and are independent of pharmacologic target (19) . In general, toxicities correlate well with pharmacokinetic or tissue distribution parameters. In primates, the primary acute effects are associated with complement activation (12, 16, 17, 20) and the systemic effects associated with accumulation of high concentrations of P=S ODNs in the kidneys (16, 23) . In rodents, the primary effect is an immune stimulation characterized by lymphoid hyperplasia and by mononuclear cell infiltrates in multiple tissues (19) . At extraordinarily high doses (15-50 times the targeted clinical doses), hepatocellular and renal tubular degeneration are evident in rodents (18, 19, 21, 35 (19, 21, 32, 35) . In general, lymphoid proliferation has been associated with stimulation of lymphocytes and appears similar to effects induced by other polyanionic compounds (11, 22, 34) . This immune stimulatory effect has been characterized in numerous studies in vitro and in vivo and involves primarily proliferation of B lymphocytes (11, 22, 34) . As part of the lymphoid proliferation, splenomegaly is observed. Histopathologic effects are characterized as hyperplasia of follicular, periarteriolar lymphoid sheath and/or marginal zone regions (Fig. 1 ) . Mononuclear (31). In some instances, the hepatic effects have been severe enough to result in morbidity and mortality (31 ) . Similarly, renal effects in mice are characterized by degeneration or necrosis in the proximal tubular epithelium (35) . In some studies, renal toxicity has been associated with mortality (35) . The mechanism of the kidney and liver toxicities is not known. However, P=S ODNs accumulate in the kidney and liver, with the greatest percentage of the dose accumulating in the liver (13, 14, 33) . The mere accumulation of P=S ODNs below the threshold for renal toxicity has not been associated with any functional renal deficits (23, 29) .
Other effects induced by P=S ODNs include a decrease in circulating platelets and alteration in the bone marrow (18, 21, 35) . Effects observed in the bone marrow include increases or decreases in total cellularity, primarily involving megakaryocytes (18, 21, 35) . This inconsistency in the effect on bone marrow cellularity does not explain a reduction in platelet formation, suggesting instead that reduction in platelets is the result of destruction or sequestration. Destruction or more rapid turnover of platelets has been suggested previously (35) , and the increase in bone marrow cellularity would be a compensatory response. As a possible mechanism for the destruction or sequestration of platelets, splenomegaly and Kupffer cell hyperplasia may play a role, and this finding has been described in several previous studies (18, 21, 35 (30) . In recent research, baboon cells in vitro did not respond to the human antisense oligonucleotide targeting c-raf kinase and the human sequence contained only a 2 basepair mismatch from the baboon (27) . However, these same cells reponded to a primate-specific oligonucleotide by specific reduction in target mRNA and protein levels. In a 4-wk toxicology study with cynomolgus monkeys, the human c-raf antisense oligonucleotide did not demonstrate reduction in levels of target mRNA (31 (16, 19, 31 ) . Therefore, there were no effects evident that might be solely attributed to a reduction of a specific mRNA. The acute effects involving inhibition of coagulation and activation of complement have been well characterized (12, 17, 20 (16, 23, 29) . The renal effects occur at doses well in excess of those used in clinical trials, and little if any alteration in renal function is evident (23, 29 
Pharmacokinetics and Toxicodynamics
The pharmacokinetics of P=S ODNs have been extensively characterized (13, 14, 33) . The pharmacokinetics, tissue distribution, and metabolism appear to differ little among different P=S ODN sequences (13, 14, 33 (14) . Elimination from the tissues appears to be primarily the result of metabolism via nucleases (14) . Plasma pharmacokinetics can be extrapolated from monkeys to humans on a body weight rather than surface area basis (14) . Therefore, preclinical data are extremely important in selection of human doses. Toxicity is predicted by either plasma concentration (inhibition of coagulation or activation of complement) or tissue concentration (hepatic and renal effects) (14, 19) .
FUTURE DIRECTIONS OF ANTISENSE THERAPEUTICS
The P=S ODNs have demonstrated pharmacologic effects via antisense mechanisms in numerous tissues or organs (3) . This effectiveness is the result of broad distribution to tissues and the stability of these agents (14) . In animal models, the P=S ODNs have a clear margin of safety, which has been borne out in clinical trials where systemic administration by intravenous infusion has been well tolerated. Formulation and/or chemical modification of antisense oligonucleotides can alter the pharmacokinetics and distribution (1, 5, 8, 28 
